– FRANCE, Paris – Mauna Kea Technologies (Euronext: MKEA), inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy platform, today announced the appointment of Joseph M. DeVivo as a Director. Mr. DeVivo is the President and Chief Executive Officer of AngioDynamics (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology.
Mr. DeVivo joins as an independent, non-executive director; all of the Company’s five directors are independent with the exception of Sacha Loiseau, CEO and founder of Mauna Kea Technologies.
“We are very pleased to welcome Joe to the Mauna Kea Technologies Board of Directors. His 20 year career as an accomplished medical device executive and business leader includes significant experience in the surgical market, expertise that complements Mauna Kea’s recently announced partnering strategy”, said Christopher D. McFadden, Chairman of the Board of Mauna Kea Technologies.
Joseph DeVivo started his career with U.S. Surgical where he held a number of senior positions in sales, marketing and R&D. He then served as President of Computer Motion Incorporated, leading a turnaround and successful merger with Intuitive Surgical. Later, Mr. DeVivo was appointed President and Chief Executive Officer of RITA Medical Systems, which he transformed into a world-leader in medical device oncology. In 2007, he was appointed as Global President of Smith & Nephew Orthopaedics. In September 2011, he was named President and Chief Executive Officer at AngioDynamics. Mr. DeVivo currently sits on the Board of Directors for AngioDynamics and the Advanced Medical Technology Association (AdvaMed), and is the Chairman of the SurgiQuest, Inc. Board of Directors.
Mauna Kea Technologies also announced the resignation of André-Michel Ballester from the Mauna Kea board. A Director since early 2011, Andre-Michel was recently named the CEO of LivaNova PLC, a global medical technology company formed through the merger of Sorin Group and Cyberonics. “On behalf of the Mauna Kea Board and executive leadership team, I would like to thank André-Michel for his invaluable contribution to the Company’s development and for his thoughtful counsel”, said Sacha Loiseau.
About Mauna Kea Technologies
Mauna Kea Technologies is a global medical device company focused on protecting patients’ lives while enabling physicians and surgeons to make better decisions thanks to direct visualization at the cellular level. The Company’s flagship product, Cellvizio, has received clearance to sell a wide range of applications in more than 40 countries, including the United States, Europe, Japan, China, Canada, Brazil and Mexico.
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.